长春高新：子公司注射用GenSci139境内生产药品临床试验获批

Core Viewpoint - Changchun Gaoxin's subsidiary, Changchun Jinsai Pharmaceutical, has received approval from the National Medical Products Administration to conduct clinical trials for the injection of GenSci139 in patients with advanced solid tumors [1] Group 1 - The approval is for the clinical trial of GenSci139, which is a single-agent treatment [1] - The clinical trial will focus on patients suffering from advanced solid tumors [1]